Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing